About SERES
Seres Therapeutics develops microbiome-based therapies that use beneficial bacteria to treat diseases, focusing on conditions like Clostridium difficile infection (CDI) and gastrointestinal disorders. Their approach aims to restore the natural balance of bacteria in the human body, addressing the root causes of these diseases. Based in Cambridge, Massachusetts, Seres collaborates with healthcare providers and research institutions to enhance its therapeutic solutions. The company's goal is to improve patient outcomes by providing effective microbiome-based treatments for unmet medical needs.
Cambridge, MassachusettsHeadquarters
2010Year Founded
$116.2MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees
Risks
Departure of Caroline Hensley may create gaps in legal and compliance oversight.
$175M Nestlé deal may increase dependency on a single partner.
Unfavorable SER-155 trial data could negatively impact investor confidence and stock prices.
Differentiation
Seres Therapeutics pioneers microbiome-based therapies, targeting root causes of diseases.
The company has a strong executive team with extensive drug development experience.
Seres operates from Cambridge, Massachusetts, with integrated research, labs, and manufacturing facilities.
Upsides
FDA Fast Track Designation for SER-155 accelerates development and review processes.
$175M Nestlé deal expands market reach for Seres' microbiome therapeutics.
Completion of SER-155 Phase 1B trial enrollment shows progress in clinical development.
Funding
Total raised$116.24 M
Latest valuation$325.00 M
StageIPO
POST IPO DEBT
3/31/2023$110
POST IPO EQUITY
10/31/2019$25
SERIES D
12/31/2014$65
$325.00 MSERIES C
11/30/2014$48
$240.00 MSERIES A
12/31/2011$6
$32.50 M